Vertex Pharmaceuticals (NASDAQ:VRTX) has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Vertex Pharmaceuticals Inc. closed 15.20% short of its 52-week high of $519.88, which the company achieved on November 8th.

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $448.40 Wednesday, on what proved to be an all-around rough trading ...

Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The layoffs will be effective on Aug. 5, according to a letter sent to the state’s Department of Labor and Training.

The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant ...